fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2006-01-27
Biotech partner: Biomira (Canada)
Pharma Partner: Merck KGaA (Germany)
Type of agreement: * commercialization/ distribution
* development
Compound: Stimuvax (liposomal vaccine BLP25)
Disease area: non-small-cell lung cancer
Development phase:  
Nature of the agreement: amendment of a license agreement
Financial terms of the agreement: The amended agreement covers Merck KGaA's funding of a phase III study with this vaccine candidate.

Go back to previous page